drugset / Trial / NCT00956436
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.
Timeline
- Start
- 2009-08
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIIB022 | Monoclonal antibody | — | Intravenous |
| Background | Sorafenib | Small molecule | — | — |